Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$159.05 USD
-2.99 (-1.85%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $158.87 -0.18 (-0.11%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Krystal Biotech, Inc. (KRYS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$182.90 | $208.00 | $153.00 | 12.87% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Krystal Biotech, Inc. comes to $182.90. The forecasts range from a low of $153.00 to a high of $208.00. The average price target represents an increase of 12.87% from the last closing price of $162.04.
Analyst Price Targets (10)
Broker Rating
Krystal Biotech, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 11 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/22/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
2/27/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
2/27/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
11/7/2023 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
9/7/2023 | Berenberg Bank | Caroline H Palomeque | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 11 |
Average Target Price | $182.90 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | 0.28 |